Physician profile
Bo Chen
NPI 1356434104
$24,665.55
in general payments reported to CMS, 2019-2025
36 companies · $3,231 in 2025
The $3,231 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,787 · 2020: $2,266 · 2021: $3,891 · 2022: $3,526 · 2023: $2,392 · 2024: $2,572 · 2025: $3,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,195.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,081.66 | 2019-2025 | Vemlidy, Livdelzi |
| Amgen INC. | $3,413.71 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $2,660.38 | 2019-2025 | Qulipta, Linzess, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,780.33 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,112.14 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $924.46 | 2019-2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $831.67 | 2019-2025 | Jardiance, Emgality |
| Glaxosmithkline, LLC. | $822.19 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $606.62 | 2020-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $556.19 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $480.42 | 2019-2023 | Steglatro, Belsomra |
| Esperion Therapeutics, INC. | $457.14 | 2021-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $398.07 | 2021-2025 | |
| Pfizer INC. | $346.68 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $337.04 | 2019-2025 | Zoryve |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bo Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.